Douglas Johnson Archive — Page 1 of 2

A bald man wearing glasses and a yellow shirt sits in a teal armchair, embracing two black-and-white dogs in a living room.
October 28, 2026

More time with the people he loves: A veteran tells his TIL therapy story, a first at Vanderbilt-Ingram Cancer Center

Senior Chief Petty Officer Ed Stift, U.S. Navy (retired), was the first patient to receive tumor-infiltrating lymphocyte (TIL) therapy at Vanderbilt-Ingram Cancer Center. Watch his story.

Person in protective laboratory clothing and mask examining a microscope slide in a blue-tinted laboratory.
June 15, 2026

People Transforming the Cancer Center

Spotlighting the people of Vanderbilt Ingram Cancer Center

Two men pose indoors: one in a dark suit and red tie, and one wearing glasses and a white University of Tennessee medical coat labeled “Douglas Johnson, MD, MSCI, Hematology-Oncology.”
June 15, 2026

New Therapy

Patient with melanoma receives tumor-infiltrating lymphocyte therapy

Olalekan Oluwole, MBBS, MPH, in a suit, stands beside Douglas Johnson, MD, MSCI, in a white medical coat, in a hospital corridor.
February 18, 2026

Patient with melanoma receives tumor-infiltrating lymphocyte therapy

The highly personalized treatment is currently approved for patients with advanced stages of melanoma whose tumors have grown despite immunotherapies and/or targeted therapies.

Rows of transparent test tubes containing blue and pink liquid, with a pink-tipped dropper above them against a blue and magenta background.
November 12, 2025

Eleven Vanderbilt scientists among this year’s ‘highly cited’ researchers

They are among 6,868 scientists worldwide whose papers rank in the top 1% by citations for their fields of research and publication year in the Web of Science Core Collection over the past 11 years.

The Vanderbilt Ingram Cancer Center (Neil Brake/Vanderbilt)
September 10, 2025

Vanderbilt-Ingram Cancer Center names associate directors and new program leaders 

Shared resources at Vanderbilt-Ingram are designed to support and enhance cancer-relevant research and scientific interaction by providing access to cutting-edge technologies and services, as well as scientific expertise.